Salivary flow (SFR)

Salivary flow is the physiological output of the major and minor salivary glands, serving as a critical process for maintaining oral health, facilitating digestion, and enabling speech [1][5]. It is not a discrete molecular target such as a protein or receptor; rather, it is a complex biological response regulated by the autonomic nervous system via the stimulation of specific receptors, most notably the Muscarinic acetylcholine receptor M3 [2]. In clinical and pharmacological research, salivary flow rate (SFR) is utilized as a primary endpoint or biomarker to assess the severity of conditions like Sjogren's syndrome and the efficacy of secretagogue therapies [2][3].\n\nPharmacological intervention typically involves the use of agonists like pilocarpine or cevimeline to restore flow in patients suffering from hyposalivation (xerostomia), or the use of anticholinergics like glycopyrrolate to manage excessive salivation (sialorrhea) [4]. Because it represents a macroscopic physiological result rather than a single molecular entity, it is classified as a clinical measure. Adequate salivary flow is essential for buffering oral pH, providing antimicrobial protection through enzymes like lysozyme, and initiating the breakdown of starches via amylase [1][5].

Other names

Salivary secretionSalivationSialogenesisSalivary flow rate

Salivary flow is modulated through the activation or inhibition of muscarinic acetylcholine receptors (primarily the M3 subtype) and adrenergic receptors within the salivary glands [1]. Parasympathomimetic drugs act as agonists at these receptors to stimulate the secretion of water and electrolytes from acinar cells, whereas anticholinergic drugs act as antagonists to reduce secretion [3][4].